The current clinical landscape of personalized cancer vaccines.

Détails

ID Serval
serval:BIB_1B87E8078A63
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
The current clinical landscape of personalized cancer vaccines.
Périodique
Cancer treatment reviews
Auteur⸱e⸱s
Fritah H., Rovelli R., Chiang C.L., Kandalaft L.E.
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Statut éditorial
Publié
Date de publication
05/2022
Peer-reviewed
Oui
Volume
106
Pages
102383
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Due to the intrinsic genetic instability of tumor cells, aberrant and novel tumor antigens can be expressed and serve as potential targets for cancer immunotherapy. This intrinsic feature can be exploited by cancer immunotherapy, particularly with cancer vaccination. Personalized cancer vaccination strategy can be a potent approach to trigger a broad-based antitumor response that is both beneficial and relevant to individual cancer patients. Also, cancer vaccination strategy can be designed to help elicit immunological memory for long-lasting tumor control. In this review, we describe the different types of personalized cancer vaccines and summarize the completed and ongoing cancer vaccination clinical trials in the last 10 years (database from www.clinicaltrials.gov). We also discuss the pros and cons of using different tumor animal models, i.e. syngeneic models, patient-derived xenografts models and genetically engineered mouse models, as tools for investigating cancer vaccination strategies. Finally, we describe preclinical studies that seek to test new emerging vaccination strategies as well as improving existing methods.
Mots-clé
Animals, Antigens, Neoplasm, Cancer Vaccines/therapeutic use, Humans, Immunotherapy/methods, Mice, Neoplasms/drug therapy, Vaccination, Autologous whole tumor, Dendritic cells, Murine tumor models, Neoantigens, Personalized cancer vaccines
Pubmed
Web of science
Open Access
Oui
Création de la notice
11/04/2022 7:48
Dernière modification de la notice
15/07/2022 5:35
Données d'usage